Compare Johnson & Johnson (JNJ) vs Wipro Limited (WIT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Johnson & Johnson vs Wipro Limited — how do they compare? Johnson & Johnson trades at $256.5 (market cap $622.84B), while Wipro Limited trades at $1.69 (market cap $16.36B). The key difference: Johnson & Johnson is far larger — about 38.1× Wipro Limited's market cap, and Wipro Limited pays the higher dividend (5.19%). Which is the better fit depends on your goals — on Pluang, investors hold Johnson & Johnson for 129 Days and Wipro Limited for 41 Days on average.
| JNJ | WIT | |
|---|---|---|
Market Cap | $622.84B | $16.36B |
Volume | 5,277,426 | 6,583,554 |
Sector | Health | Technology |
52-Week High | $278.43 | $3.06 |
52-Week Low | $186.00 | $1.61 |
Typical Hold Time | 129 Days | 41 Days |
Enterprise Value | $651.12B | $14.47B |
Dividend Yield | 2.07% | 5.19% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Johnson & Johnson (JNJ) trades at $256.48, up 0.67% with a bearish technical signal despite recent earnings beats. The stock shows strong fundamentals with 21.48% net income margin and 25.74% ROE, though valuation metrics appear elevated with P/E of 29.98. Recent news highlights pipeline strength including Icotyde's potential $4.5B peak sales and Q3 earnings anticipation.
JNJ offers stable dividend income and pharmaceutical innovation upside, but faces patent cliff risks and elevated valuation. Analyst consensus targets $286.53 (11.7% upside) with 52.5% buy ratings. Key risks include biosimilar competition for Stelara and debt-to-asset ratio increase to 24.06% in 2025.
Wipro (WIT) trades at $1.67, down 0.6% with bearish technical signals despite recent AI productivity gains. The company reported $890.88B revenue for 2025 with solid 13.92% net margins and reasonable valuation (P/E 12.78). Recent quarters show earnings misses, but cash flow remains strong at $25.02B. Analyst sentiment is mixed with only 19% buy ratings.
Wipro faces execution risks amid competitive IT services market, though AI initiatives show promise. The stock offers value pricing but requires earnings acceleration to justify higher multiples. Near-term performance depends on client spending recovery and AI deployment success.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Johnson & Johnson
Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →About Wipro Limited
Wipro is a leading global IT services provider, with 175,000 employees. Based in Bengaluru, this India IT services firm leverages its offshore outsourcing model to derive over half of its revenue (57%) from North America. The company offers traditional IT services offerings: consulting, managed services, and cloud infrastructure services as well as business process outsourcing as a service.
Read more on WIT →
